2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 8, 2017

11:00AM-12:30PM: Abstract Number: 2960

Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

11:00AM-12:30PM: Abstract Number: 2988

Characteristics of People with Work-Related Versus Non-Work Related Carpal Tunnel Syndrome: National Health Interview Survey, 2010 & 2015

ARHP Epidemiology and Public Health

11:00AM-12:30PM: Abstract Number: 2980

Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 2939

Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2973

Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

11:00AM-12:30PM: Abstract Number: 2948

Distinct Trajectories of Medial Fixed Joint Space Width Loss over Four Years of Follow-up Among Knees with and at Risk for Knee Osteoarthritis

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2947

Do Bone Marrow Lesions Reactivate Endochondral Ossification Leading to Osteophyte Genesis? Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2955

Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients

Patient Outcomes, Preferences, and Attitudes III

11:00AM-12:30PM: Abstract Number: 2953

Drivers of Satisfaction with Care in Lupus

Patient Outcomes, Preferences, and Attitudes III

11:00AM-12:30PM: Abstract Number: 2941

Effect of Achieving Sustained SDAI Remission on Erosion Repair in Patients with Early RA: A Prospective HR-pQCT Study

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2969

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

11:00AM-12:30PM: Abstract Number: 2981

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Fasscinate Trial

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 2956

Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

11:00AM-12:30PM: Abstract Number: 2957

Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-up of Neonatal Lupus

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

11:00AM-12:30PM: Abstract Number: 2989

Hydration and Gout: Looking at New Modes of Uric Acid Management

ARHP Epidemiology and Public Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].